Sun Yat-sen University: Lymphoma trials

The registry lists 58 Lymphoma studies with Sun Yat-sen University as lead sponsor. 26 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 38Phase 3 3No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3ANot yet recruitingNCT06961500Phase 2
• A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCLRecruitingNCT06855823Phase 1/2
• Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: a Phase II StudyRecruitingNCT06848569Phase 2
• Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaRecruitingNCT06846489Phase 2
• Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06793956Phase 1
• Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular LymphomaNot yet recruitingNCT06757894Phase 2
• Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLRecruitingNCT06742502Phase 2
• Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
• High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)Not yet recruitingNCT06646211Phase 2
• A Prospective Study: Sintilimab and R-CHOP in PMBCL TreatmentNot yet recruitingNCT06412068Phase 2
• Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTLRecruitingNCT06406556Phase 2
• A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaRecruitingNCT05900765Phase 2
• Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT05572983Phase 2
• Assessment of Early-detection Based on Liquid Biopsy in Lymphoid MalignanciesRecruitingNCT05275036
• The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical StudyRecruitingNCT04957901
• A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CTRecruitingNCT04843267Phase 2
• Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell LymphomaRecruitingNCT04736914Phase 2
• PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHLRecruitingNCT04624984Phase 2
• Prognostic Nomogram of Extranodal NK/T-cell LymphomaRecruitingNCT04554511
• A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)RecruitingNCT04365036Phase 3
• Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
• A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBLRecruitingNCT03971318
• A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCLRecruitingNCT03971305
• Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCLRecruitingNCT03958916
• PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T LymphomaRecruitingNCT02705508Phase 2
• Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic LymphomaRecruitingNCT02396043Phase 2
• A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical TrialsCompletedNCT05827341
• Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid TumorsActive, not recruitingNCT05620862Phase 1
• A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP TherapyStatus unknownNCT05527912Phase 2
• A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell LymphomaStatus unknownNCT05527275Phase 1/2
• Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell LymphomaActive, not recruitingNCT05464433Phase 1/2
• PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT05156554Not applicable
• Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCLStatus unknownNCT05093140Phase 2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
• Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With LymphomaStatus unknownNCT04797182Phase 2
• DLBCL Treatment in Children and AdolescentsCompletedNCT04726995
• Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLStatus unknownNCT04676789Phase 2
• A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab EraStatus unknownNCT04624971
• Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCLActive, not recruitingNCT04624958Phase 2
• A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's LymphomaCompletedNCT04469543
• Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell LymphomaStatus unknownNCT04423549
• Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell LymphomaStatus unknownNCT04423536
• A Multicenter Prospective Study of "High Risk" Molecular Typing in Patients With Adult T Lymphoblastic LymphomaStatus unknownNCT04320992
• Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLCompletedNCT04022005Phase 2
• GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCLStatus unknownNCT04021992Phase 2
• Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2
• Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknownNCT03321890Phase 2
• Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHLStatus unknownNCT03245905Phase 2
• P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma PatiensTerminatedNCT02533323Phase 2
• Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early StageTerminatedNCT02359162Phase 3
• Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX ChemotherapyStatus unknownNCT02229682Phase 2
• Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTLStatus unknownNCT02080234Phase 2
• GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell LymphomaStatus unknownNCT01991158Phase 2
• Avastin+ GemAOD As First-Line Treatment in NK/T Cell LymphomaStatus unknownNCT01921790Phase 2
• A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma PatientsStatus unknownNCT01793844
• A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma PatientsStatus unknownNCT01788137Phase 3
• Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's LymphomaCompletedNCT01761500Phase 2
• Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell LymphomaStatus unknownNCT01322776Phase 1/2